InterAtrial Shunt Device (IASD®) implantation — a novel treatment method for heart failure with preserved ejection fraction

Kosowski, Michał; Kübler, Piotr; Kołodziej, Adam; Krakowiak, Bartosz; Kustrzycka‐Kratochwil, Dorota; Sławin, Janusz; Sokolski, Mateusz; Biegus, Jan; Zymliński, Robert; Banasiak, Waldemar; Ponikowski, Piotr; Reczuch, Krzysztof

doi:10.5603/kp.a2017.0096

Cited by 2 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IASD has been shown to decrease PCWP in patients with HFpEF. [16][17][18] In phase 2 randomized control clinical trial within the REDUCE LAP HF-I study, Feldman et al found that patients who received IASDs had significantly greater reductions in (PCWP) during exercise than those in the control group (p = 0.028). 17 These findings are consistent with another study within the REDUCE LAP HF-I trial, in which Kaye et al demonstrated that IASD placement significantly reduced PCWP and left ventricular enddiastolic volume.…”

Section: Percutaneous Interventions For Rcm and Hcmmentioning

confidence: 99%

“…The IASD has been shown to decrease PCWP in patients with HFpEF 16–18 . In phase 2 randomized control clinical trial within the REDUCE LAP HF‐I study, Feldman et al found that patients who received IASDs had significantly greater reductions in (PCWP) during exercise than those in the control group ( p = 0.028) 17 .…”

Section: Percutaneous Interventions For Rcm and Hcmmentioning

confidence: 99%

“…However, sustained improvements in hemodynamics have not yet been shown in the long term. IASDs have also been associated with improvements in non‐hemodynamic outcomes 16–19 . Kaye et al reported that IASD use led to sustained improvements in New York Heart Association Heart Failure class, six‐minute walk distance, and quality of life 16 .…”

Section: Percutaneous Interventions For Rcm and Hcmmentioning

confidence: 99%

“…IASDs have also been associated with improvements in non-hemodynamic outcomes. [16][17][18][19] and quality of life. 16 A list of interatrial shunts discussed in the literature is provided in Table 1.…”

Section: Percutaneous Interventions For Rcm and Hcmmentioning

confidence: 99%

See 3 more Smart Citations

Mechanical and interventional support for heart failure with preserved ejection fraction: A review

et al. 2022

View full text Add to dashboard Cite

Introduction Restrictive cardiomyopathy (RCM) and hypertrophic cardiomyopathy (HCM) are two disease processes that are known to progress to heart failure with preserved ejection fraction (HFpEF). Pharmacologic therapies for HFpEF have not improved patient outcomes or reduced mortality in this patient cohort; thus, there continues to be substantial interest in other treatment strategies, including surgical interventions and devices. In this article, we explore and report the current utility of percutaneous therapies and surgically implanted mechanical support in the treatment of patients with HFpEF. Results Treatment strategies include percutaneous interventions with interatrial shunts, left atrial assist devices (LAADs), and ventricular assist devices (VADs) in various configurations. Although VADs have been employed to treat patients with heart failure with reduced ejection fraction, their efficacy is limited in those with RCM and HCM. A left atrial‐to‐aortic VAD has been proposed to directly unload the left atrium, but data is limited. Alternatively, a LAAD could be placed in the mitral position and simultaneously unload the left atrium, while filling the left ventricle. Conclusion A left atrial assist device in the mitral position is a promising solution to address the hemodynamic abnormalities in RCM and HCM; these pumps, however, are still under development.

show abstract

Section: Percutaneous Interventions For Rcm and Hcmmentioning

confidence: 99%

Section: Percutaneous Interventions For Rcm and Hcmmentioning

confidence: 99%

Section: Percutaneous Interventions For Rcm and Hcmmentioning

confidence: 99%

Section: Percutaneous Interventions For Rcm and Hcmmentioning

confidence: 99%

See 2 more Smart Citations

Mechanical and interventional support for heart failure with preserved ejection fraction: A review

et al. 2022

View full text Add to dashboard Cite

show abstract

Heart Failure with Preserved Ejection Fraction—a Concise Review

et al. 2020

View full text Add to dashboard Cite

Purpose of Review Heart failure with preserved ejection fraction (HFpEF) is a relatively new disease entity used in medical terminology; however, both the number of patients and its clinical significance are growing. HFpEF used to be seen as a mild condition; however, the symptoms and quality of life of the patients are comparable to those with reduced ejection fraction. The disease is much more complex than previously thought. In this article, information surrounding the etiology, diagnosis, prognosis, and possible therapeutic options of HFpEF are reviewed and summarized. Recent Findings It has recently been proposed that heart failure (HF) is rather a heterogeneous syndrome with a spectrum of overlapping and distinct characteristics. HFpEF itself can be distilled into different phenotypes based on the underlying biology. The etiological factors of HFpEF are unclear; however, systemic low-grade inflammation and microvascular damage as a consequence of comorbidities associated with endothelial dysfunction, oxidative stress, myocardial remodeling, and fibrosis are considered to play a crucial role in the pathogenesis of a disease. The H 2 FPEF score and the HFpEF nomogram are recently validated highly sensitive tools employed for risk assessment of subclinical heart failure. Summary Despite numerous studies, there is still no evidence-based pharmacotherapy for HFpEF and the mortality and morbidity associated with HFpEF remain high. A better understanding of the etiological factors, the impact of comorbidities, the phenotypes of the disease, and implementation of machine learning algorithms may play a key role in the development of future therapeutic strategies.

show abstract

InterAtrial Shunt Device (IASD®) implantation — a novel treatment method for heart failure with preserved ejection fraction

Cited by 2 publications

References 21 publications

Mechanical and interventional support for heart failure with preserved ejection fraction: A review

Mechanical and interventional support for heart failure with preserved ejection fraction: A review

Heart Failure with Preserved Ejection Fraction—a Concise Review

Contact Info

Product

Resources

About